"The design and results of the monarchE study are practice-changing and represent the first advancement in adjuvant treatment of HR+ HER2- breast cancer in a very long time," said Sara M. Tolaney, MD, MPH, Harvard Medical School, Dana-Farber Cancer Institute, and investigator on the monarchE study.
"Ukwakheka nemiphumela yocwaningo lwe-monarchE kuyashintsha futhi kumele inqubekela phambili yokuqala ekwelashweni okwenziwe ngomdlavuza webele kwabakwa-HR + HER2 esikhathini eside kakhulu," kusho uSara M. Tolaney, MD, MPH, Harvard Medical School, Dana- I-Farber Cancer Institute, nomphenyi ocwaningweni lwe-monarchE.